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Abstract
Background:  Cytomegalovirus (CMV) pneumonitis has been shown to be associated with
lymphocytic alveolitis after lung transplantation. In the present study, we investigated a series of
bronchoalveolar (BAL) and blood samples, collected in the absence of rejection or acute infectious
episodes. in order -1: to evaluate intra-alveolar cell population changes concomitant with CMV
replication and -2: to reappraise the value of cell population analysis in the management of patients
after lung transplantation.
Methods:  We used flow cytometry to investigate modifications of lymphocyte subpopulations
related to pulmonary cytomegalovirus infections in blood and BAL samples from a series of 13 lung
transplant recipients. After exclusion of samples obtained during pulmonary rejection, bronchiolitis
obliterans or acute bacterial infection, 48 blood and BAL samples were retained for analysis: 17
were CMV positive by shell-vial assay and 31 were CMV negative in blood and BAL.
Results:  Our results demonstrate that pulmonary CMV infection is associated with a significant
increase in the total lymphocyte population in BAL samples, but with minor modifications of the
various lymphocyte subpopulations and a significantly higher absolute number of B lymphocytes in
blood samples.
Conclusions:  Cytomegalovirus pulmonary infection is accompanied by only minor changes in BAL
lymphocyte subpopulations. The study of BAL lymphocyte subpopulations therefore appears to be
of limited clinical value in the diagnosis of pulmonary CMV infection. However, increased blood B-
lymphocytes seems to be a clinical feature associated with CMV infection.
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Background
Cytomegalovirus (CMV) infections are the most frequent
viral infections in lung transplant recipients [1]. Studies
in man and the murine model of CMV have demonstrat-
ed that development of pathological effects is not exclu-
sively related to viral replication in the lung, and a host
immune response is required for induction of pneumoni-
tis [2,3]. For instance, CMV pneumonitis has been
shown to be associated with lymphocytic alveolitis after
bone marrow transplantation [4] or lung transplantation
[5]. In murine models of CMV pneumonitis, increased
numbers of both CD4+ T helper and CD8+ suppressor/
cytotoxic pulmonary lymphocytes have been observed
[6]. Moreover, in non-HIV immunodepressed patients,
it has been shown that CD8+ T lymphocytes play a par-
ticularly important role in host defense against cytomeg-
alovirus infection [7–9] and cytotoxic CD8+ T
lymphocytes are activated in situ during CMV pneumo-
nia [10]. However, after lung transplantation, the cellu-
lar alveolar modifications related to CMV replication
have not been clearly characterized, particularly com-
pared to those associated with rejection [11–13]. Bron-
choalveolar lavage (BAL) has been largely developed in
the management of lung transplant recipients and in the
investigation of alveolar cells, particularly in order to de-
tect an opportunistic infection, such as CMV pneumoni-
tis [1]. All patients transplanted in our institution are
routinely evaluated by BAL for detection of opportunistic
infection and routine analysis of the various subsets of
intra-alveolar cells, particularly lymphocytes. In the
present study, we investigated a series of BAL and blood
samples collected in the absence of rejection or acute in-
fectious episodes, in order -1: to evaluate intra-alveolar
cell population changes concomitant with CMV replica-
tion and -2: to reappraise the value of cell population
analysis in the management of patients after lung trans-
plantation.
Methods
Patients and specimen collection
The lung transplantation protocol was approved by the
institutional review board for human studies and in-
formed consent was obtained from the subjects after de-
tailed description of the procedure. According to French
legislation, this study did not need Comité Consultatif de
Protection des Personnes dans la Recherche Biomédicale
(C.C.P.P.R.B.) approval.
Thirteen lung transplant recipients (4 females, 9 males)
were studied, with a mean follow-up of 15 months
(range: 1 to 42 months). The median age of the patients
was 27 years (range: 18–56). The patient characteristics
are reported in Table 1. The immunosuppressive regi-
men consisted of cyclosporin (whole blood level between
200 to 300 ?g/L), azathioprine (1.5 – 2 mg/kg/d), and
steroids (started at d+5 at 0.2–0.3 mg/kg/d, up to 1 mg/
kg/d at d+21 until the third month; doses were then ta-
pered to 0.2 mg/kg at 6 months) with the additional peri-
operative infusion of antilymphocyte globulins
(Thymoglobulines Mérieux 2.5 mg/kg/d for 5 days).
Acute rejection was treated with IV pulses of methyl-
prednisolone (15 mg/kg/d) for 3 consecutive days. Every
episode of CMV infection was treated by intravenous
ganciclovir, 5 mg/kg every 12 h for 14 days. Maintenance
therapy (5 mg/kg/d) was initially provided for patients
suffering from recurrent CMV infection.
Routine bronchoscopy with BAL and transbronchial bi-
opsy (TBB) were performed at regular intervals after
transplantation (monthly during the first 6 months, eve-
ry 3 months until the end of the first year, then twice a
year) to monitor for infection and rejection, and when
clinically indicated. Peripheral blood samples were col-
lected at the time of each bronchoscopy and at the at-
tending physician's discretion. BAL fluids were analyzed
for evidence of infection, differential cell counts, and
lymphocyte marker studies, when possible. Peripheral
blood lymphocyte markers were analyzed simultaneous-
ly.
Nine of the 13 patients studied developed a total of 36
CMV infections in blood or BAL or both. Four patients
never developed CMV infections.
One hundred and twenty-two blood samples (median: 8
per patient, range: 1–17 per patient) and 107 BAL sam-
ples (median: 7 per patient, range: 1–17 per patient) were
collected over the study period for CMV culture. Fifty
nine BAL samples were excluded for the studyowing to
the presence of concomitant pulmonary rejection (n =
36), bronchiolitis obliterans (n = 11), bacterial pnumonia
(n = 1), other viral infection (n = 1), or insufficient recov-
ery rate of cells from BAL to allow differential cell counts
and lymphocytes marker studies (n = 10). Forty-eight
blood and BAL samples from 12 of the 13 patients were
analyzed, as the 13th patient, who always suffered from
concomitant pulmonary rejection, was excluded from
the study.
Viral cultures
Rapid CMV culture by the shell vial technique was used
for BAL fluid and blood, as previously described [14].
Definition of CMV infection
CMV infection was defined as the detection of CMV in
blood or BAL fluid by culture [15]. CMV pneumonitis was
defined as CMV infection and the presence of character-
istic cytomegalic inclusion-bearing cells on cytologic ex-
amination of BAL specimens or histopathologic
examination of transbronchial biopsy specimens [15].BMC Infectious Diseases 2001, 1:15 http://www.biomedcentral.com/1471-2334/1/15
Lymphocyte immunotyping by flow cytometry
Lymphocyte subsets in BAL and blood were evaluated by
multiparameter analysis of leukocytes by flow cytometry
using a Coulter Profile II cytometer (Coulter Cytometry
Products; Coultronics France SA, Margency, France).
Following gentle mixing, 100 µl of each whole blood
specimen or 0.5 ×  106 BAL cells were incubated with 10
µl of monoclonal antibody at room temperature for 15
min before lysis using the Coulter Q-Prep procedure. The
following monoclonal antibodies – all conjugated with
fluorescein isothiocyanate (FITC) or phycoerythrin
(RD1) – (Coulter Cyto-Stat/Coulter clone; Coultronics
France SA, Margency, France) were used: T11-RD1/B4-
FITC (anti human CD2/CD19), anti human CD3 (IgG1)-
FITC, T4-RD1/T8-FITC (anti human CD4/CD8), T8-
FITC/S6F1-RD1 (anti human CD8/CD11a), NKH-1-RD1
(anti human CD56), TiGammaA.1-FITC (anti human Ti-
GammaA). The cells were analyzed on forward-angle
light scatter and 90° light scatter using a lymphocyte
gate.
We focused our attention on surface adhesion molecules,
particularly LFA-1, since the absence of cell surface LFA-
1 has been proposed as a mechanism of escape from im-
munosurveillance [16]. The S6F1 (CD11a) lymphocyte
surface antigen reacts with the LFA-1 antigen and is ex-
pressed on approximately 10% of unfractionated T cells,
15% of CD4+ cells and 50% of CD8+ cells. [17]. The S6F1
antibody can distinguish killer effector (CD8+/S6F1+)
cells from the precursor of killer effector (CD8+/S6F1-)
cells among CD8+ T lymphocytes [17]. NKH-1 (CD56)
defining a natural killer cell antigen, is expressed on a
Table 1: Characteristics of lung transplant recipients entering the present study
Patient Age Sex Disease CMV CMV Samples Follow-up Steroid
(yr) status* infection studied (mo) dose
episodes (mg/kg)
† (n) **
DR B A L B A L
CMV CMV
+ (n) - (n)
1 25 M Idiopathic pulmonary + + 1 1 0 1 0.7 (-)
fibrosis
2 53 M Paracicatricial + + 2 1 2 17 0.2
emphysema (0.2–0.5)
3 56 F Lymphangiomyomatosis + + 8 4 ‡ 6 19 0.35
(0.2–15)
4 18 F Cystic fibrosis + - 5 2 2 11 0.2
(0.2–0.9)
5 48 M Idiopathic pulmonary - + 4 2 2 5 0.9
fibrosis (0.3–15)
6 20 M Cystic fibrosis - + 4 2 1 5 0.8
(0.8–1)
7 42 M Panlobular emphysema - + 4 2 2 15 0.25
(0.2–0.9)
8 37 F Primary pulmonary - + 6 3 2 16 0.2
hypertension (0.2–15)
9 27 M Cystic fibrosis - - 0 0 2 7 0.3
(0.2–0.4)
10 42 M Centrolobular - - 0 0 1 24 0.2 (-)
emphysema
11 24 F Cystic fibrosis - - 0 0 5 30 0.2
(0.2–1)
12 23 M Cystic fibrosis - - 0 0 6 42 0.2
(0.2–0.2)
* CMV status at time of transplantation: D, donor; R, recipient; GVH, graft-versus-host. † Total number of CMV infection episodes in the patient 
during the follow-up; ‡ One sample was taken into account as BAL became CMV positive 8 days later; ** expressed as median (min-max)BMC Infectious Diseases 2001, 1:15 http://www.biomedcentral.com/1471-2334/1/15
subpopulation of peripheral blood large granular lym-
phocytes demonstrating natural killer activity [18]. Anti-
NKH-1 was found to react with approximately 12% of cir-
culating lymphocytes and more than 90% of circulating
NKH-1+ cells are large granular lymphocytes [18].
Anti human TiGammaA recognizes an antigenic deter-
minant carried by a T Cell Receptor (TCR) γ  chain. This
antibody delineates a unique subset accounting for ap-
proximately 3% of human circulating lymphocytes [19].
The TiGammaA epitope is expressed on approximately
two-thirds of the circulating CD3+ TCR-α /β -fraction
[19].
As a sufficient recovery rate of cells from BAL and a lym-
phocyte percentage > 3–5% are required to allow reliable
flow cytometry processing, immunotyping of alveolar
lymphocytes could only be performed on 22 BAL sam-
ples (11 CMV+ samples and 11 CMV-samples).
Statistical analysis
Results are expressed as mean ± SEM. Comparisons of
quantitative data were performed using a Mann-Whit-
ney U test for unpaired data or a Wilcoxon's signed-rank
test for paired data. A P value < 0.05 was considered sig-
nificant.
Results
Study population
Seventeen of the 48 blood and BAL samples were CMV
positive by culture (referred to as CMV+ samples): 12 in
BAL, 4 in blood and BAL, and 1 in blood only. However,
this last sample was taken into account because BAL be-
came CMV positive 8 days later. Thirty-one samples
were negative in blood and BAL (referred to as CMV-
samples). Four ± 0.7 blood and BAL samples were ob-
tained per patient (range 1 to 10) between 1 to 42 months
of follow-up after transplantation; 6 months ± 1 (range 1
to 15) for CMV+ samples versus 11 months ± 2 (range 1 to
42) for CMV-samples (P < 0.05). Seven samples were
taken during antiviral treatment (2 CMV+ samples and 5
CMV-samples). A statistical analysis was unable to show
that antiviral treatment influences the cell counts. Four
of the patients with CMV infection had characteristic cy-
tomegalic inclusion-bearing cells on cytologic examina-
tion of BAL or histopathologic examination of
transbronchial biopsy specimens, and were therefore
considered to present CMV pneumonitis [15].
Differential cell counts in BAL and blood samples
Results of differential cell counts in BAL are reported in
Table 2. An increased percentage of alveolar lym-
phocytes was observed in CMV + samples compared to
CMV-samples (14.8 ± 3.4 versus 5.3 ± 0.6%, P < 0.001).
For the 4 episodes of CMV pneumonia, the percentage of
alveolar lymphocytes was 11 ± 3%, and number of alveo-
lar lymphocytes was 40 ± 9 ×  103/mL. The blood WBC
count was 6.68 ± 0.7 and 6.97 ± 0.7 ×  109/L (NS), and the
absolute lymphocyte count was 0.60 ± 0.07 and 0.59 ±
0.08 ×  109/L (NS) in CMV+ and CMV-samples, respec-
tively.
Lymphocyte subset counts in blood and BAL
As shown in Table 3, CMV+ blood samples had a signifi-
cantly higher B lymphocyte count (CD19+ cells); while
CMV-samples tended to have higher natural killer lym-
phocyte (CD56+ cells) and TiGammaA+ lymphocyte
counts. No difference was observed for CD8+ or CD4+
lymphocytes, expressed as percentage or in absolute
numbers. CD11a was expressed on approximately 50% of
CD8+ T lymphocytes in CMV+ and CMV-samples. The
absolute number of CD8+ T lymphocytes in BAL was sig-
nificantly higher in CMV+ samples (Table 3). Twenty
percent of CD8+ T lymphocytes expressed CD11a.
CD4/CD8 and CD8/CD3 ratios in BAL versus blood
CMV+ samples had a lower CD4/CD8 ratio in BAL than
in blood (p = 0.008), and a higher CD8/CD3 ratio in BAL
than in blood (p = 0.002). In contrast, no significant dif-
ference was found between BAL and blood for either
CD4/CD8 or CD8/CD3 ratios in CMV-samples. Compar-
isons of CD4/CD8 and CD8/CD3 ratios in BAL and
blood were not statistically different between CMV+ and
CMV-samples.
Discussion
In the present study, BAL and blood lymphocyte subpop-
ulations from lung transplant recipients with or without
CMV pulmonary infection, but without graft rejection or
bacterial infection, were compared. Lymphocytes were
increased in bronchoalveolar fluid from patients with
CMV pulmonary infection, but surprisingly only minor
Table 2: Differential cell counts in BAL from CMV+ and CMV-ep-
isodes (mean ± SEM).
CMV+ CMV- P value
Total cell count (103/
ml)
422 ± 64 383 ± 45 NS
Lymphocytes (%) 14.8 ± 3.4 5.3 ± 0.6 < 0.001
Alveolar macrophages 
(%)
76.5 ± 5.2 87.9 ± 2.6 0.03
Neutrophils (%) 8.7 ± 3.3 6.6 ± 2.6 NS
Siderophages* (%) 37 ± 84 7  ± 6N S
*: Siderophages, characterized by deep green-blue staining after Perl's 
reaction, were expressed as the percentage of the total macrophage 
population. NS: non significant (p > 0.1)BMC Infectious Diseases 2001, 1:15 http://www.biomedcentral.com/1471-2334/1/15
changes were observed in the distribution of the various
subpopulations. In contrast, blood B-lymphocytes were
significantly increased during CMV infection.
A significant increase in alveolar lymphocytes, expressed
either in absolute number or as a percentage, was ob-
served in the BAL fluid sampled concurrently with CMV
infection. Such an increase has already been reported in
pulmonary CMV infection and during acute rejection
[5,12,13]. The presence of lymphocytic alveolitis is there-
fore considered to be useless to differentiate rejection
from CMV infection. An increase in pulmonary CD8+ T
lymphocytes during CMV infection has previously been
reported [13], and CD8+ cytotoxic lymphocyte counts
were found to be increased during CMV pneumonia [10].
However, interestingly, we found that pulmonary CMV
infection was associated with only minor modifications
in the respective alveolar lymphocyte subpopulations
limited to a slight increase in the CD8+T lymphocyte
subpopulation. The change in the CD4/CD8 ratio reflects
an increase in the CD8 lymphocyte subset rather than a
decrease in T helper lymphocytes [13]. As demonstrated
by the differences in the CD4/CD8 and CD8/CD3 lym-
phocyte ratios in blood and BAL during CMV infection,
the higher CD8+ T lymphocyte count in BAL is highly
suggestive of local pulmonary recruitment.
The cellular changes observed in our studies suggest a
slight increase in cell-mediated immune effectors in the
lungs [2,3]. Pulmonary CMV infection primes the host
immune system, either in a CMV-specific or non-specific
fashion [20–23] and several arguments are in favor of a
CMV-specific immune response of the recipient as it has
been previously shown that CD8+ T lymphocytes play an
important role in host defense against CMV infection [7–
9]. Lymphocyte proliferation kinetic studies have also
shown accumulation of primed CMV-specific lym-
phocytes within the lung allograft during CMV infection
[22]. However, in the present study, no difference was
observed in terms of the absolute number of activated cy-
totoxic (CD8+/CD11a+) lymphocytes. This could be a
consequence of either pharmacological immunosup-
pression or CMV "per se" [24]. Alternatively, the cellular
changes observed in the alveolar spaces may be related to
a CMV-induced alloreaction which could provide a non-
virus-specific response [23]. It has been demonstrated
that alveolar macrophages are activated during pulmo-
nary CMV infection [10,12] and secrete cytokines such as
IL-6, IL-1, and TNF-?? which could therefore promote
the recruitment and maturation of CD8+ cytotoxic lym-
phocytes [10]. Moreover, endothelial cells can be infect-
ed with CMV [25] and may be the target of alloreactive
cytotoxic lymphocytes [26], which could subsequently
migrate to alveolar spaces.
Gamma/delta T lymphocytes tend to be more numerous
in the blood of patients without infection; however, their
role and function during CMV infection are largely un-
Table 3: Lymphocyte counts and lymphocyte subsets counts in blood and BAL.
CMV+ samples * CMV-samples * P value
Lymphocytes in blood † (/mm3) 602 ± 75 590 ± 80 NS
CD2+ blood (/mm3) 428 ± 64 [69 ± 4%] 480 ± 73 [77 ± 3%] NS
CD3+ blood (/mm3) 414 ± 64 [66 ± 4%] 421 ± 61 [74 ± 3%] NS
CD4+ blood (/mm3) 192 ± 39 [30 ± 3%] 188 ± 29 [33 ± 3%] NS
CD8+ blood (/mm3) 210 ± 32 [35 ± 3%] 209 ± 28 [37 ± 3%] NS
CD19+ blood (/mm3) 126 ± 23 [23 ± 3%] 74 ± 13 [16 ± 3%] 0.02
CD8/CD11a+ blood (/mm3) 134 ± 26 [60 ± 5%] 105 ± 17 [48 ± 5%] NS
NKH-1+ blood (/mm3)3   ± 0.8 [0.6 ± 0.15%] 7.3 ± 1.9 [1.3 ± 0.3%] 0.1
Tiγ A1 + blood (/mm3)5 . 7   ± 1.5 [1.1 ± 0.3%] 25 ± 8 [3.4 ± 0.7%] 0.08
Lymphocytes in BAL ‡ (×  103/ml) 69.5 ± 19 27.4 ± 3.9 0.04
CD2+ BAL (×  103/ml) 64.3 ± 19 [90 ± 3%] 25.2 ± 3.7 [91 ± 1%] 0.1
CD3+ BAL (×  103/ml) 60.4 ± 18 [82 ± 3%] 22.1 ± 4.2 [81 ± 3] 0.1
CD4+ BAL (×  103/ml) 11.6 ± 5.6 [14 ± 2%] 4.2 ± 0.8 [18 ± 4%] NS
CD8+ BAL (×  103/ml) 49.4 ± 13.2 [69 ± 4%] 17.6 ± 3.9 [60 ± 7%] 0.04
CD19+ BAL (×  103/ml) 0.06 ± 0.03 [0.2 ± 0.01] 0.1 ± 0.03 [0.5 ± 0.12] NS
CD8/CD11a+ BAL (×  103/ml) 13 ± 7 [20 ± 10%] 2 ± 0.5 [18 ± 10%] NS
NKH-1+ BAL (×  103/ml) 1 ± 0.5 [1.7 ± 0.9%] 0.3 ± 0.01 [1.3 ± 0.4%] NS
Tiγ A1+ BAL (×  103/ml) 0.9 ± 0.4 [1.2 ± 0.3] 1.2 ± 0.7 [4.4 ± 3%] NS
*: Respective percentages given in brackets †: Lymphocyte subset counts in blood were determined in 17 CMV+ samples and 31 CMV-samples. ‡: 
Lymphocyte subset counts in BAL were determined in only 11 CMV+ samples and 11 CMV-samples. NS: non significant (p > 0.1)BMC Infectious Diseases 2001, 1:15 http://www.biomedcentral.com/1471-2334/1/15
known. Recently, it has been demonstrated that gamma/
delta T cell expansion in kidney allograft recipients fol-
lows CMV infection and could possibly be an immuno-
logic consequence of this infectious disorder [27].
Lastly, our finding of a poor inflammatory response to
pulmonary CMV infection could be in agreement with
the hypothesis that CMV pneumonia is not exclusively a
consequence of an immunopathological process [28,29].
In the present study, the BAL samples collected in 4 pa-
tients during CMV pneumonia showed a particularly low
percentage of alveolar lymphocytes.
In the present study, blood B lymphocytes were signifi-
cantly increased during CMV infection. The effects of
CMV infection on B-cell differentiation have not yet been
extensively studied [30]. However, there is some evi-
dence that CMV can directly activate B-cells in vitro
[31,32]. This response to CMV infection seems to consist
of polyclonal activation of B cells, as previously demon-
strated [32] and confirmed by us after κ /λ  staining of
these B-lymphocytes (J-F Bernaudin, personal results),
which could probably be responsible for anti-CMV anti-
body secretion [32,33]. Interestingly, such an event was
not observed in the alveolar space, in which B lym-
phocytes were almost entirely absent. As lymphocyte im-
munotyping by flow cytometry is rapid and easy,
monitoring of variations in blood B-lymphocyte counts
could therefore be indicative of CMV infection.
Conclusion
An increase in blood B-lymphocytes appears to be a clin-
ical feature of pulmonary CMV infection. In contrast,
pulmonary CMV infection is accompanied by only minor
changes in BAL lymphocyte subpopulations. In our ex-
perience, evaluating the main subsets of alveolar lym-
phocytes therefore appears to be of limited clinical value
in the diagnosis of pulmonary CMV infection.
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